New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Agulnik, Mark

doi:10.1007/s12032-012-0159-2

Cited by 52 publications

(38 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy is used in 3 different settings: induction therapy, concomitant chemo-radiotherapy, and sequential treatment, which consists induction chemotherapy followed by concomitant chemo-radiotherapy (1)(2)(3)(4). Recently, the incorporation of cetuximab to induction and/or concomitant phase of chemoradiation has been an area of interest (5)(6)(7)(8). Cetuximab is an IgG1 monoclonal antibody against the ligand binding domain of EGFR and it is currently the only US Food and Drug Administration approved EGFR inhibitor for the treatment of HNSCC.…”

Section: Contextmentioning

confidence: 99%

“…Cetuximab is an IgG1 monoclonal antibody against the ligand binding domain of EGFR and it is currently the only US Food and Drug Administration approved EGFR inhibitor for the treatment of HNSCC. The EGFR, a member of the ErbB family of receptor tyearosine kinases, is overexpressed in up to 90% of HNSCC (5,9). In this article, the studies that evaluated the role of cetuximab for locally advanced and metastatic /recurrent HN-SCC will be reviewed.…”

Section: Contextmentioning

confidence: 99%

See 1 more Smart Citation

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Larizadeh

2017

Int J Cancer Manag

View full text Add to dashboard Cite

Context: Treatment outcome for locally advanced squamous cell carcinoma of the head and neck is poor. Recently, anti-epidermal growth factor monoclonal antibodies, such as cetuximab have been used to improve outcome. Evidence Acquisition: Medline, EMBASE, and SCOPUS were searched to identify published studies that evaluated cetuximab for loco regionally advanced and metastatic/recurrent squamous cell carcinoma of head and neck. Only published studies in English between 1990 and 2016 were included. Results: Cetuximab may be administered concomitantly with radiation alone or in combination with chemotherapy during the induction phase of sequential modalities. Also, it has been used in combination with chemotherapy as first line or second line for treatment of metastatic/recurrent patients. Conclusions: Cetuximab can be incorporated at some points in the course of treatment of patients with squamous cell carcinoma of the head and neck. The best protocols and the appropriate patients remain to be defined.

show abstract

Section: Contextmentioning

confidence: 99%

Section: Contextmentioning

confidence: 99%

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Larizadeh

2017

Int J Cancer Manag

View full text Add to dashboard Cite

show abstract

“…Therefore, knockdown of MRP2 may influence the sensitivity of cancer cells to 5-FU. Epidermal growth factor receptor (EGFR), which is one of most well-studied receptor tyrosine kinases, promotes cancer cell growth and is associated with drug resistance (19). Thus, it has emerged as a significant target for the development of anticancer therapy (20).…”

Section: Enhancing Chemosensitivity In Oral Squamous Cell Carcinoma Bmentioning

confidence: 99%

Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2

Chen

Lovel

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Oral cancer is the eighth most common type of cancer among men worldwide, with an age-standardized rate of 6.3 per 100,000, and is the fourth leading cause of cancer-associated mortality among men in Taiwan. Cisplatin and 5-fluorouracil (5-FU) are two of the most frequently utilized chemotherapy drugs for the treatment of oral cancer. Although oral cancer patients initially benefit from chemotherapy with these drugs, they may develop resistance to them, which worsens their prognosis and reduces survival rates. It has been reported that increased levels of epidermal growth factor receptor (EGFR) and multidrug resistance-associated protein 2 (MRP2) induce drug resistance in numerous types of human cancer. Therefore, the present study employed lentivirus vector-mediated RNA interference (RNAi) in order to target the genes encoding EGFR and MRP2 in the oral squamous cell carcinoma cell line OC2. It was observed that RNAi-mediated downregulation of EGFR or MRP2 increased the sensitivity to 5-FU and cisplatin in OC2 cells. Downregulation of EGFR resulted in significant suppression of OC2 tumor growth following 5-FU administration. However, simultaneous downregulation of the two genes did not further suppress the tumor growth, indicating that MRP2 does not have a significant role in the chemosensitivity of EGFR-downregulated cells to 5-FU. In contrast, downregulation of MRP2 was demonstrated to significantly enhance the therapeutic effects of cisplatin in EGFR-downregulated OC2 tumors. The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi-mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer. IntroductionOral cancer is the eighth most common type of cancer among men worldwide, with an age-standardized rate of 6.3 per 100,000 (1,2), and is the fourth leading cause of cancer-associated mortality among men in Taiwan (3). In addition, oral cancer has been ranked highest with respect to the rates of incidence and mortality among men aged 25-44 years in Taiwan since 2005 (3). Chemotherapy has been used as the primary treatment for patients exhibiting recurrent or metastatic cancers, including oral cancer (4). Of the various chemotherapy drugs available, cisplatin and 5-fluorouracil (5-FU) are the two most frequently utilized for the treatment of oral cancer (5). However, the efficacy of cancer chemotherapy is often limited by the development of drug resistance by the cancer cells in clinical practice (6).It has been demonstrated that multidrug resistance results largely from the expression of adenosine triphosphate-binding cassette (ABC) transporters with broad drug specificity (7-9). Multidrug resistance-associated protein 2 (MRP2), a member of the ABC transporter superfamily, has been observed in various tumors to confer resistance to a number of therapeutic drugs, including cisplatin (10-12). The levels of MRP2 messenger (m)RNA in certain hum...

show abstract

“…Second-generation TKIs relevant to SCCHN, including lapatinib, afatinib, and dacomitinib, target multiple ErbB members and in the case of afatinib and dacomitinib irreversibly so (Table 4.1; Fig. 4.2) [136], [176].…”

Section: Tyrosine Kinase Inhibitors (Tkis) Targeting Egfrmentioning

confidence: 99%

EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer

Liu

Cracchiolo

Beck

et al. 2014

Molecular Determinants of Head and Neck Cancer

View full text Add to dashboard Cite

Squamous cell carcinoma of the head and neck (SCCHN) is one of the more challenging cancers to treat. Although great progress has been made over the years, available treatment options are still far from ideal, as epitomized by a 5-year survival rate of only 30-40 %. A unique feature of SCCHN is that elevated expression of the epidermal growth factor receptor (EGFR), a member of the ErbB receptor tyrosine kinase (RTK) family and highly relevant to oncogenic proliferation, occurs in a significant number of cases, which has prompted great interest in utilizing EGFR-targeted therapies to treat this devastating disease. Significant advances in the treatment of SCCHN have been made using EGFR-targeting monoclonal antibodies. Another class of EGFR-targeting inhibitors, tyrosine kinase inhibitors (TKIs), has also shown promise as a potential treatment option. In order to appreciate how these therapeutic agents work and why they fail when they do, it is crucial to explore the biology of the ErbB family members, the signaling pathways that are associated with them, and how they interact with each specific therapeutic agent. This chapter discusses the biology of EGFR and other ErbB family members in SCCHN, and summarizes the current status of the application of EGFR and ErbB inhibitors.Keywords Epidermal growth factor receptor (EGFR) · Squamous cell carcinoma of the head and neck (SCCHN) · Tyrosine kinase inhibitor (TKI) · Monoclonal antibodies · Erlotinib · Cetuximab · Radiation · Cisplatin · ErbB family

show abstract

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Cited by 52 publications

References 72 publications

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2

EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer

Contact Info

Product

Resources

About